Literature DB >> 29775980

[Comparison of the Masaoka-Koga Classification with the New TNM Staging of the IASLC/ITMIG for Thymoma and Thymic Carcinoma].

Michael Ried1, Maria-Magdalena Eicher1, Reiner Neu1, Dietmar Kraus2, Sebastian Inderhees2, Alexander Marx3, Hans-Stefan Hofmann1,4.   

Abstract

BACKGROUND: The Masaoka-Koga classification describes the extent and spread of thymic epithelial malignancies. The objective of this study was to evaluate the Masaoka-Koga and the new TNM-staging system regarding differences in stage distributions, clinical implementation and therapeutic consequences.
METHODS: Retrospective analysis of all patients who underwent surgery between January 2005 and December 2015 for thymoma/thymic carcinoma in two centres for thoracic surgery. The final tumour stages were determined on the basis of preoperative imaging, surgical reports and histological findings.
RESULTS: A total of 118 patients (male 51%) with a mean age of 56 ± 14.8 years were included. Indications for surgery were primary mediastinal tumour (n = 97), pleura dissemination (n = 15) or mediastinal recurrence (n = 7). Radical tumour resection was performed in 92% of patients (n = 109) within one operation, whereas 8% of patients (n = 9) underwent two operations. Surgical revision was necessary in 12 patients (10.1%) and in-hospital mortality was 1.7% (n = 2). Early Masaoka-Koga stages I (n = 34) and II (n = 16) shifted to the new UICC stage I (T1: n = 58). Locally advanced stages (Masaoka-Koga stage III n = 22 vs. UICC stage IIIA + IIIB n = 20) and metastasised stages (Masaoka-Koga stage IV n = 36 vs. UICC stage IV n = 39) remained very similar.
CONCLUSIONS: The new TNM staging system gave rise to changes, especially in early stages (downstaging), but these had no therapeutic implications. Although advanced stages were very similar, the new TNM staging provides more clinically relevant differentiation. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 29775980     DOI: 10.1055/a-0606-5603

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  4 in total

1.  Risk stratification of thymic epithelial tumors by using a nomogram combined with radiomic features and TNM staging.

Authors:  Qijun Shen; Yanna Shan; Wen Xu; Guangzhu Hu; Wenhui Chen; Zhan Feng; Peipei Pang; Zhongxiang Ding; Wenli Cai
Journal:  Eur Radiol       Date:  2020-08-05       Impact factor: 5.315

2.  Identification of Immune-Related Hub Genes in Thymoma: Defects in CD247 and Characteristics of Paraneoplastic Syndrome.

Authors:  Lin-Fang Deng
Journal:  Front Genet       Date:  2022-06-14       Impact factor: 4.772

Review 3.  "Radiotherapy for thymic epithelial tumors: What is the optimal dose? A systematic review."

Authors:  A Angrisani; R Houben; F Marcuse; M Hochstenbag; J Maessen; D De Ruysscher; S Peeters
Journal:  Clin Transl Radiat Oncol       Date:  2022-03-19

4.  Does size affect the prognosis of resectable thymoma beyond the eighth edition TNM?

Authors:  Yen-Chiang Tseng; Han-Shui Hsu; Yi-Hsuan Lin; Yen-Han Tseng; Chih-Wen Shu; Yih-Gang Goan; Ching-Jiunn Tseng
Journal:  Thorac Cancer       Date:  2021-12-20       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.